Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020 Share, Trends, Segmentation, Top Key Players, Growth and Forecast To 2025

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market is valued at USD 589.6 Million in 2018 and expected to reach USD 892.5 Million by 2025 with the CAGR of 6.1% over the forecast period.

Increasing prevalence rate of amyotrophic lateral sclerosis (ALS) disease, surge in the awareness about ALS treatment and growing demand for personalized treatment drugs with rising geriatric populations are the major factors driving the growth of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market.

Get Sample of This Report@ https://brandessenceresearch.com/requestSample/PostId/1151

Scope of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report–

Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that progressively degenerate the muscles and impacts physical body function. The disease is also known as Motor Neuron or Lou Gehrig’s disease. The ALS mostly occurs between 40-60 age groups and sometimes it can develop in early age also due to inheritance of the genetic mutation. The disease causes the damage of nerve cells, brain and spinal cord which impact the difficulty in breathing, swallowing, speaking, and mobility. The ALS disease is mainly of two types depending upon its cause, that is sporadic, familial, and many others. The main cause of developing the ALS disease is disorganized immune response, chemical imbalance with higher levels of glutamate in the body, mishandling of proteins and some of the risk factors includes exposure to viral agents, vigorous physical activity, and trauma. Currently, no cure available for the treatment of the ALS disease but the drugs, advanced stem cell therapy and some physical therapy can reduce the symptoms of the disease.

Global amyotrophic lateral sclerosis (ALS) treatment market report cover prominent players,

Omega Protein Corporation, Sun Pharma, Lunan Pharma, Pfizer, Mitsubishi Tanabe Pharma, Glemark Generics, Apotex, Covis Pharma, Others

According to recent research on ALS treatment of Sanford Burnham Prebys Medical Discovery Institute in May 2019, identified a protein called membralin plays vital role to prevent the symptoms. Hence the gene therapy using this membralin gives a potential therapeutic direction to treat this deadly disease.

The regions covered in global amyotrophic lateral sclerosis (ALS) treatment market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, global amyotrophic lateral sclerosis (ALS) Treatment  market sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Segmentation:–

By Treatment Type: Drugs and Medications, Baclofen, Rilutek, Tiglutik, Radicava, Stem cell therapy, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, OthersGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics–

The major factors driving the growth of global amyotrophic lateral sclerosis (ALS) treatment market are increasing prevalence of amyotrophic lateral sclerosis (ALS) disease and surge in the awareness about ALS treatment and growing demand for personalized treatment drugs with rising geriatric populations. According to the WHO in 2010, the geriatric population was an estimated 524 million and the number is expected to rise to triple by 2050, to about 1.5 billion, representing 16% of world’s population. According to Centers for Disease Control and Prevention (CDC) in 2014, the prevalence of ALS was an estimated 5 cases per 100000 populations globally. The ALS disease has higher prevalence in the developed countries due to presence of sedentary lifestyle increases the risk the geriatric population, which creates a demand for novel therapeutics approaches and targeted treatment medications for ALS. According to ALS Association, the ALS has affected between 2 and 5 people in every 100,000 worldwide whereas around 5,000 people receives a diagnosis annually.

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Regional Analysis–

North America is expected to dominate the global amyotrophic lateral sclerosis (ALS) treatment market with the potential rate due to rising prevalence of ALS disease due to presence of sedentary lifestyle, increasing the geriatric population which has high the risk of developing this ALS disorder in this region followed by Europe. According to the Centers for Disease Control and Prevention in 2016, the prevalence of ALS was estimated between 14,500 and 15,000 people in the United States and approximately 5,000 people in the U.S. are diagnosed with ALS annually followed by Europe and Asia Pacific.

Full Research Report @ https://brandessenceresearch.com/healthcare/amyotrophic-lateral-sclerosis-als-treatment-market-size

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com

Website: https://brandessenceresearch.com/

Article: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Comments are closed